6 completed, 2 unknown. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Unknown 2 |
Follow IDN 5109: new trials by email Literature Review of IDN 5109 trials Research Report on IDN 5109
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Efficacy Study Of Ortataxel In Recurrent Glioblastoma Ortataxel - Glioblastoma | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 45 | 2013-11-01 | 2019-10-23 |
| Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients BAY59-8862 (Cytotoxic Taxane) - Breast Neoplasms, Breast Cancer, Metastatic | Phase 2 | Completed | Bayer | 82 | 2002-04-01 | 2014-12-23 |
| BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer ortataxel - Lung Cancer | Phase 2 | Completed | Roswell Park Cancer Institute | 2002-03-01 | 2022-09-26 | |
| Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma Taxane (Cytotoxic, BAY59-8862) - Lymphoma, Non-Hodgkin | Phase 2 | Completed | Bayer | 29 | 2002-02-01 | 2013-10-14 |
| BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma ortataxel - Lymphoma | Phase 2 | Unknown | Theradex | 2002-01-01 | 2008-07-24 | |
| BAY 59-8862 in Treating Patients With Advanced Kidney Cancer ortataxel - Kidney Cancer | Phase 2 | Unknown | Theradex | 2001-12-01 | 2008-07-24 | |
| Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma Bay 59-8862 - Carcinoma, Renal Cell | Phase 2 | Completed | Bayer | 54 | 2001-12-01 | 2014-12-19 |
| Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients BAY59-8862 (Cytotoxic Taxane) - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Bayer | 102 | 2001-12-01 | 2009-06-22 |
Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Glioblastoma (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Immunoblastic (1) · Lymphoma, Mantle-Cell (1) · Neoplasm Metastasis (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Bayer (4) · Theradex (2) · Mario Negri Institute for Pharmacological Research (1) · Roswell Park Cancer Institute (1)
Canada (5) · United States (5) · Germany (4) · Italy (3) · United Kingdom (3) · France (2) · Israel (2) · Netherlands (2) · Greece (1) · Poland (1) · Spain (1) · Switzerland (1)
Antonio Silvani, MD (1) · Marius Moscovici, MD (1) · Nithya Ramnath, MD (1) · Rasim Ahmet Gucalp, MD (1)